Effect of Proliferator-Activated Receptor-g Pro12Ala Polymorphism on Colorectal Cancer Risk

Abstract

Source of support: Departmental sources Background: The association between peroxisome proliferators-activated receptor g (PPARg) Pro12Ala polymorphism and colorectal cancer (CRC) risk is still controversial. A meta-analysis was performed. Material/Methods: We conducted a literature search using PubMed, EMBASE, and Cochran databases. The pooled odds ratio (OR) with 95 % confidence intervals (CIs) were calculated. Fixed-effects and random-effects models were used. Dominant model, recessive model, and additive model were used in this meta-analysis. Results: Fifteen studies including 13575 cases and 17085 controls were included in our meta-analysis. Result of this me-ta-analysis found that PPARg Pro12Ala polymorphism was significantly associated with a reduced risk of CRC (OR=0.90; 95 % CI 0.83–0.98; P=0.01). No significant association was found between PPARg Pro12Ala polymor-phism and CRC risk in Asians (OR=0.80; 95 % CI 0.60–1.09; P=0.15). However, PPARg Pro12Ala polymorphism was significantly associated with a reduced risk of CRC in Caucasians (OR=0.91; 95 % CI 0.83–0.99; P=0.03). When stratified analysis was performed by CRC site, no positive association was found between PPARg Pro12Ala polymorphism and rectal cancer (OR=0.95; 95 % CI 0.74–1.22; P=0.71). However, a reduced risk of colon can-cer was observed (OR=0.85; 95 % CI 0.76–0.94; P=0.002)